Wang, Yan
Ni, Haiqing
Zhou, Shuaixiang
He, Kaijie
Gao, Yarong
Wu, Weiwei
Wu, Min
Wu, Zhihai
Qiu, Xuan
Zhou, Ying
Chen, Bingliang
Pan, Donghui
Huang, Chenrong
Li, Mingzhu
Bian, Yicong
Yang, Min
Miao, Liyan
Liu, Junjian http://orcid.org/0000-0002-7093-0508
Funding for this research was provided by:
National Key New Drug Creation and Manufacturing Program, Ministry of Science and Technology (2017ZX09304021)
Jiangsu Provincial Medical Innovation Team (CXTDA2017024)
Leading technology foundation research project of Jiangsu province (BK20192005)
Article History
Received: 12 April 2020
Accepted: 20 July 2020
First Online: 6 August 2020
Compliance with ethical standards
:
: Haiqing Ni, Shuaixiang Zhou, Kaijie He, Yarong Gao, Weiwei Wu, Min Wu, Zhihai Wu, Xuan Qiu, ying Zhou, Bingliang Chen, and Junjian Liu are employees of Innovent Biologics (Suzhou). All the remaining authors have declared no conflicts of interest.
: All mice experiments were performed in accordance with the regulations for care and use of laboratory animals at Innovent Biologics and were approved by Innovent’s Institutional Animal Care and Use Committee (IACUC-01). All monkey experiments were approved by IACUC and performed according to the regulation of AAALAC.
: NOS-SCID mice and NOG mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Human CD47 knock-in mice were purchased from Biocytogen, Inc. (Beijing, China). Cynomolgus monkeys were purchased from Beijing Prima Biotech Inc.
: RAJI, A375, CCRF-CEM, and H292 cell lines were obtained from ATCC (Manassas, VA). CHO-S cell line was obtained from Themo Fisher Scientific, Carlsbad, CA, USA). MC38 cell line was obtained from Shanghai Model Organisms Center, Inc. (Shanghai, China). PBMC cells were purchased from Allcells (Alameda, CA, USA).